September 25, 2024 11:33 AM EDTUpdated September 26, 12:15 PM
R&D

Novo's semaglu­tide shows po­ten­tial in chron­ic skin con­di­tion in obese pa­tients

Katherine Lewin

News Reporter

A small study con­duct­ed by re­searchers at St. Vin­cent’s Uni­ver­si­ty Hos­pi­tal in Dublin sug­gests that No­vo Nordisk’s GLP-1 semaglu­tide could treat a com­mon and chron­ic …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

As­traZeneca’s Truqap edges clos­er to prostate can­cer la­bel ex­pan­sion with Phase 3 win

A service from the Financial Times